IsoPlexis

IsoPlexis is a life sciences company developing novel single-cell omics analysis technologies with the aim of revolutionizing cancer immunotherapy. By developing world-leading precision diagnostic testing and analysis systems, the company builds a collaborative bridge between engineering informatics, research, and clinicians to comprehensively evaluate and monitor patients' clinical responses, such as clinical biomarker analysis and prediction, to help improve the diagnosis and treatment of cancer and other refractory diseases. Based on the IsoCode chip detection technology, it can capture the complete biomolecular and functional information of individual cells, including dynamically monitoring immune T-cells and analyzing the overall immune function characteristics of individual patients, thereby enabling comprehensive evaluation and monitoring of patient clinical responses to assist in the treatment of cancer and other refractory diseases.